What is Moleculin Biotech Inc?
, a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.22M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 3999,999 shares |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |